These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 28574300)

  • 21. Novel CD123-aptamer-originated targeted drug trains for selectively delivering cytotoxic agent to tumor cells in acute myeloid leukemia theranostics.
    Wu H; Wang M; Dai B; Zhang Y; Yang Y; Li Q; Duan M; Zhang X; Wang X; Li A; Zhang L
    Drug Deliv; 2017 Nov; 24(1):1216-1229. PubMed ID: 28845698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bispecific antibody-targeted T-cell therapy for acute myeloid leukemia.
    Kubicka E; Lum LG; Huang M; Thakur A
    Front Immunol; 2022; 13():899468. PubMed ID: 36389764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the alpha subunit of IL-3 receptor (CD123) in patients with acute leukemia.
    Aldoss I; Clark M; Song JY; Pullarkat V
    Hum Vaccin Immunother; 2020 Oct; 16(10):2341-2348. PubMed ID: 32692611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells.
    Kovtun Y; Jones GE; Adams S; Harvey L; Audette CA; Wilhelm A; Bai C; Rui L; Laleau R; Liu F; Ab O; Setiady Y; Yoder NC; Goldmacher VS; Chari RVJ; Pinkas J; Chittenden T
    Blood Adv; 2018 Apr; 2(8):848-858. PubMed ID: 29661755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123.
    Gauthier L; Virone-Oddos A; Beninga J; Rossi B; Nicolazzi C; Amara C; Blanchard-Alvarez A; Gourdin N; Courta J; Basset A; Agnel M; Guillot F; Grondin G; Bonnevaux H; Bauchet AL; Morel A; Morel Y; Chiron M; Vivier E
    Nat Biotechnol; 2023 Sep; 41(9):1296-1306. PubMed ID: 36635380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.
    Tettamanti S; Marin V; Pizzitola I; Magnani CF; Giordano Attianese GM; Cribioli E; Maltese F; Galimberti S; Lopez AF; Biondi A; Bonnet D; Biagi E
    Br J Haematol; 2013 May; 161(3):389-401. PubMed ID: 23432359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission.
    Xie LH; Biondo M; Busfield SJ; Arruda A; Yang X; Vairo G; Minden MD
    Blood Cancer J; 2017 Jun; 7(6):e567. PubMed ID: 28574487
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of SGN-CD123A, A Potent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia.
    Li F; Sutherland MK; Yu C; Walter RB; Westendorf L; Valliere-Douglass J; Pan L; Cronkite A; Sussman D; Klussman K; Ulrich M; Anderson ME; Stone IJ; Zeng W; Jonas M; Lewis TS; Goswami M; Wang SA; Senter PD; Law CL; Feldman EJ; Benjamin DR
    Mol Cancer Ther; 2018 Feb; 17(2):554-564. PubMed ID: 29142066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD123 Antagonistic Peptides Assembled with Nanomicelles Act as Monotherapeutics to Combat Refractory Acute Myeloid Leukemia.
    Xu S; Zhang M; Fang X; Hu X; Xing H; Yang Y; Meng J; Wen T; Liu J; Wang J; Wang C; Xu H
    ACS Appl Mater Interfaces; 2022 Aug; 14(34):38584-38593. PubMed ID: 35977045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The human polynucleotide kinase/phosphatase (hPNKP) inhibitor A12B4C3 radiosensitizes human myeloid leukemia cells to Auger electron-emitting anti-CD123 ¹¹¹In-NLS-7G3 radioimmunoconjugates.
    Zereshkian A; Leyton JV; Cai Z; Bergstrom D; Weinfeld M; Reilly RM
    Nucl Med Biol; 2014; 41(5):377-83. PubMed ID: 24637100
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.
    Thokala R; Olivares S; Mi T; Maiti S; Deniger D; Huls H; Torikai H; Singh H; Champlin RE; Laskowski T; McNamara G; Cooper LJ
    PLoS One; 2016; 11(8):e0159477. PubMed ID: 27548616
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia.
    He SZ; Busfield S; Ritchie DS; Hertzberg MS; Durrant S; Lewis ID; Marlton P; McLachlan AJ; Kerridge I; Bradstock KF; Kennedy G; Boyd AW; Yeadon TM; Lopez AF; Ramshaw HS; Iland H; Bamford S; Barnden M; DeWitte M; Basser R; Roberts AW
    Leuk Lymphoma; 2015 May; 56(5):1406-15. PubMed ID: 25248882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Auger electron-emitting (111)In-DTPA-NLS-CSL360 radioimmunoconjugates are cytotoxic to human acute myeloid leukemia (AML) cells displaying the CD123(+)/CD131(-) phenotype of leukemia stem cells.
    Gao C; Leyton JV; Schimmer AD; Minden M; Reilly RM
    Appl Radiat Isot; 2016 Apr; 110():1-7. PubMed ID: 26748017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeted inhibition of ULK1 enhances daunorubicin sensitivity in acute myeloid leukemia.
    Qiu L; Zhou G; Cao S
    Life Sci; 2020 Feb; 243():117234. PubMed ID: 31887299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia.
    Arcangeli S; Rotiroti MC; Bardelli M; Simonelli L; Magnani CF; Biondi A; Biagi E; Tettamanti S; Varani L
    Mol Ther; 2017 Aug; 25(8):1933-1945. PubMed ID: 28479045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical value of CD25/CD123 co-expression in acute myeloid leukemia patients.
    Aref S; Azmy E; El Ghannam D; Haroun M; Ibrahim L; Sabry M
    Cancer Biomark; 2020; 29(1):9-16. PubMed ID: 32417762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD123 redirected multiple virus-specific T cells for acute myeloid leukemia.
    Zhou L; Liu X; Wang X; Sun Z; Song XT
    Leuk Res; 2016 Feb; 41():76-84. PubMed ID: 26740053
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
    Al-Mawali A; Gillis D; Lewis I
    J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia.
    Lin TY; Zhu Y; Li Y; Zhang H; Ma AH; Long Q; Keck J; Lam KS; Pan CX; Jonas BA
    Nanomedicine; 2019 Aug; 20():102004. PubMed ID: 31055076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Co-Delivery of Daunorubicin and Homoharringtonine in Folic Acid Modified-Liposomes for Enhancing Therapeutic Effect on Acute Myeloid Leukemia.
    Liu Q; Luo L; Gao X; Zhang D; Feng X; Yang P; Li H; Mao S
    J Pharm Sci; 2023 Jan; 112(1):123-131. PubMed ID: 35469834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.